Skip to content
The Kids Research Institute Australia logo
Donate

Discover . Prevent . Cure .

Search

Research

A randomized, controlled, phase 1/2 trial of a neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents

Factor H binding protein (also known as LP2086) is a conserved outer membrane neisserial lipoprotein that has emerged as a strong candidate protein antigen...

Research

Hospitalisation for bronchiolitis in infants is more common after elective caesarean delivery

The authors previously reported an increased risk of hospitalisation for acute lower respiratory infection up to age 2 years in children delivered by...

Research

A genomics-based approach to assessment of vaccine safety and immunogenicity in children

This methodology has significant potential to identify covert interactions between inflammatory pathways triggered by vaccination, and as such may be a...

Research

IgG Responses to Pneumococcal and Haemophilus Influenzae Protein Antigens Are Not Impaired in Children with a History of Recurrent Acute Otitis Media

Vaccines including conserved antigens from Streptococcus pneumoniae & nontypeable Haemophilus influenzae have the potential to reduce of otitis media.

Research

Reduced levels of antimicrobial proteins and peptides in human cord blood plasma

Reduced levels of antimicrobial proteins and peptides in human cord blood plasma.

Research

Assessment of the potency and potential immunomodulatory effects of the Measles Mumps Rubella-Varicella vaccine in infants

This study compared the potency and immunomodulatory effects of measles mumps rubella (MMR) vaccine given to infants alone or in combination with varicella...

Research

A DTPa-HBV-IPV vaccine for primary vaccination of infants

Combined vaccines have an increasingly important role to play in delivering these antigens acceptably.

Research

Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review

A combined DTPa-IPV booster vaccine was administered as a 4th or 5th dose after DTPa or DTPw priming.